Business Wire

HIBER

2.11.2020 09:02:06 CET | Business Wire | Press release

Share
World’s First End-to-End IoT Subscription Service for Remote Monitoring Launched by Hiber With Oil & Gas Well Integrity Monitoring to Prevent Leakage & Build a More Sustainable Practice

Dutch satellite Internet-of-Things (IoT) solution startup, Hiber , today announces the launch of HiberHilo , its first end-to-end solution for Oil & Gas Well Integrity Monitoring. HiberHilo is also the world’s first subscription service for IoT-enabled remote Oil/Gas Well monitoring and the company will be introducing similar services for other specific use cases in 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005336/en/

There is a growing demand for remote monitoring in industries such as Oil & Gas to create more sustainable and environmentally friendly practices, especially with COVID-19 limiting travel halting routine maintenance checks. However, the IoT SaaS market in this space is nascent and lacks simplicity. Having already been one of the first firms to develop a remote IoT connectivity solution with the launch of its proprietary nano-satellites in 2018, Hiber identified the urgent need for readily available out-the-box end-to-end subscription based offerings. These must be designed bespoke for particular use cases, as well as being simple and efficient for businesses to install and implement.

The HiberHilo solution for Oil & Gas Well Integrity Monitoring is the first offering of this kind that Hiber will launch because this process is currently complex, time-consuming and expensive (costing up to $40,000 per field visit). Additionally, manual monitoring is prone to error and is often not conducted frequently enough.

Monitoring is critical to ensure that anomalies are identified early and addressed - this can include potential leaks which, if left unaddressed, can impact people’s health and safety as well as negatively impact the environment. HiberHilo’s out-of-the-box subscription solution utilises Hiber’s global satellite network to empower organisations to automate continuous annulus pressure and wellhead monitoring of up to 250 wells in a radius of 10km, even in the most remote locations on Earth. Pricing starts at $449 per month per well (1 sensor and a 5 year contract).

The all-in-one product is available as both a starter kit and in the form of an enterprise solution, both of which feature:

  • A pressure and optional temperature sensor to ensure accurate and regular measurements - organisations can add more sensors to the network if required
  • Easy connectivity anywhere, sending up to 24 messages a day or one per hour
  • Alarm and alert settings
  • An intuitive dashboard for desktop and mobile
  • Support both on-site and via mobile

Coen Janssen, co-founder and Chief Strategy Officer at Hiber said , “We are excited to launch this first-of-its-kind IoT proposition for remote monitoring at a time when it is needed more than ever. HiberHilo has already been proven by Nederlandse Aardolie Maatschappij (NAM) and Royal Dutch Shell (better known as just “Shell”) on an abandoned on-shore well. This technology can be installed in less than 2 hours and within 0.25% accuracy levels of a traditional wired system, which is extremely reliable.”

“We look forward to more companies embracing this new proposition as it will save them time, money and lives by allowing teams to monitor well integrity from home as well as reducing the risk of well integrity issues to create more sustainable practices. The future for remote monitoring is very bright!”

Hiber entered the market in 2018 purely as a connectivity provider, utilising its own proprietary nano-satellite technology to unlock IoT connectivity in the 90% of the world without it. For more information on HiberHilo visit: hiberhilo.com or watch this video .

-- ENDS --

About Hiber

Hiber is an Internet of Things (IoT) solution startup, founded and led by a dream team of satellite experts and tech entrepreneurs. These 'Hibernauts' are working on a moonshoot goal: to launch and provide end-to-end IoT solutions connected by satellites in space. More than 55 employees work on the ground-breaking technology behind Hiber and Hiberband at its offices in the Netherlands and USA.

To date, the company has managed to attract significant funding. This has meant that in November 2018 Hiber became the Netherlands’ first commercial satellite company, launching its first two nano-satellites into orbit. Hiber officially launched at the Amazon Web Services’ (AWS) Re:invent Conference in November 2018 where they were named Commercial Startup Launch of 2018 at the AWS conference.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye